疫苗市场规模、份额和成长分析（按类型、给药途径、年龄层和地区划分）－2026-2033年产业预测

预计到 2024 年，全球疫苗市场规模将达到 791.9 亿美元，到 2025 年将达到 841.8 亿美元，到 2033 年将达到 1372.4 亿美元，预测期（2026-2033 年）的复合年增长率为 6.3%。

全球疫苗市场正经历显着成长，这主要得益于公众健康意识的提高、感染疾病和慢性病的增加以及研发投入的强劲增长。各国政府和卫生组织制定的疫苗接种政策旨在预防感染疾病爆发并改善社区健康，凸显了经济效益的重要性。 mRNA等创新技术以及公私合营正在创造机会，以满足尚未满足的需求，尤其是在开发中国家。旨在提高疫苗可及性的项目，包括针对面临经济障碍的儿童的项目，有助于减少健康差距。然而，高昂的研发成本和监管障碍等挑战可能会阻碍中小企业进入市场。随着全球卫生安全合作的加强，对能够提供可扩展解决方案的有效疫苗的需求持续增长，这凸显了疫苗产业在应对新出现的健康威胁方面发挥的重要作用。

全球疫苗市场驱动因素

全球疫苗市场正经历显着成长，其主要驱动力是多种疾病感染病例的快速增加，包括流感、人类乳突病毒（HPV）、肝炎以及新冠病毒（COVID-19）和猴痘等新出现的病毒。公众日益认识到免疫接种在减轻医疗负担方面的重要作用，促使各国政府和卫生组织加强疫苗接种计划，以遏制疾病爆发。此外，在许多发展中地区，全球疫苗免疫联盟（GAVI）等组织的措施正在促进民众获得必要的疫苗，从而推动市场扩张。随着病原体的不断演变和新威胁的出现，全面覆盖疫苗接种的需求变得日益重要，这将推动公共和私人医疗保健领域的持续成长。

全球疫苗市场面临的限制

全球疫苗市场面临诸多限制因素，其中疫苗研发过程漫长而复杂，需要投入大量科学研究资源与资金。这个漫长的过程涉及众多临床试验、监管核准以及复杂的低温运输物流，所有这些都给生产商带来了沉重的经济负担。由于许多候选疫苗在临床试验阶段失败，这些投资最终都变成了沉没成本。此外，生物製药的生产需要先进的基础设施和熟练的劳动力，这使得中小企业难以有效参与竞争。因此，高成本和研发成本可能会抑制创新和市场成长，尤其是在应对新出现的病原体时。

全球疫苗市场趋势

随着疫苗技术的进步，特别是mRNA平台在新冠疫情期间的成功应用，全球疫苗市场正经历一场意义深远的变革时期。这促使製药和生物技术公司大力投资于创新疫苗技术，包括mRNA疫苗、病毒载体疫苗、DNA疫苗和奈米颗粒疫苗。这些技术不仅提高了疫苗的有效性和安全性，还加快了对新兴感染疾病的应对速度，并推动了个人化疫苗的研发。生物技术的进步正在将疫苗市场的结构向下一代平台转型，从而推动研发投入的增加和策略联盟的建立，以确保在这一充满活力的领域中获得竞争优势。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 专利分析
• 监管分析
• 技术分析
• 案例研究
• 顾客购买行为分析

全球疫苗市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 结合疫苗
• 重组疫苗
• 灭活疫苗和次单位疫苗
• 减毒活病毒疫苗
• 类毒素疫苗
• 病毒载体疫苗
• mRNA疫苗
• 其他疫苗

全球疫苗市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 多价疫苗
• 单价疫苗

全球疫苗市场规模（依疾病适应症划分）及复合年增长率（2026-2033 年）

• 肺炎链球菌感染
• 流感
• 联合疫苗
• HPV
• 病菌感染
• 带状疱疹
• 轮状病毒
• MMR
• 水痘
• 肝炎
• DTP
• 脊髓灰质炎
• RSV
• 其他疾病适应症

全球疫苗市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服给药（PO）
• 鼻腔给药途径（NAS）
• 皮下给药途径（皮下）
• 肌肉内注射

全球疫苗市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 成人疫苗
• 儿童疫苗

全球疫苗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• GSK Plc（UK）
• Merck & Co., Inc.（US）
• Pfizer Inc.（US）
• Sanofi（France）
• CSL（Australia）
• Emergent（US）
• Johnson & Johnson Services, Inc.（US）
• AstraZeneca（UK-Sweden）
• Serum Institute of India Pvt., Ltd.（India）
• Bavarian Nordic（Denmark）
• Daiichi Sankyo Company, Limited（Japan）
• Panacea Biotec（India）
• Biological E Limited（India）
• Bharat Biotech（India）
• Novavax（US）
• Inovio Pharmaceuticals（US）
• Sinovac（China）
• Incepta Pharmaceuticals Ltd.（Bangladesh）
• Valneva SE（France）
• Bio Farma（Indonesia）

结论与建议

Global Vaccines Market size was valued at USD 79.19 Billion in 2024 and is poised to grow from USD 84.18 Billion in 2025 to USD 137.24 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global vaccine market is witnessing significant growth driven by heightened public health awareness, an increase in infectious and chronic diseases, and robust investments in R&D. Vaccination policies established by governments and health organizations aim to prevent outbreaks and enhance community health, underscoring economic benefits. Innovative technologies like mRNA and collaborative efforts through public-private partnerships create opportunities for unmet market needs, particularly in developing nations. Programs facilitating access to vaccines, such as initiatives for children facing economic barriers, enhance health equity. However, challenges like high development costs and regulatory hurdles can hinder market entry for smaller players. As collaboration intensifies in global health security, the demand for effective vaccines that offer scalable solutions continues to rise, emphasizing the industry's critical role in addressing emerging health threats.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccines Market Segments Analysis

Global Vaccines Market is segmented by Technology, Type, Disease Indication, Route of Administration, End User, and region. Based on Technology, the market is segmented into Conjugate Vaccines,Recombinant Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Viral Vector Vaccines, MRNA Vaccines, and Other Vaccines. Based on Type, the market is segmented into Multivalent Vaccines, and Monovalent Vaccines. Based on Disease Indication, the market is segmented into Pneumococcal Disease, Influenza, Combination Vaccines, HPV,Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, RSV, and Other Disease Indications. Based on Route of Administration, the market is segmented into Oral Route (PO), Intranasal Route (NAS), Subcutaneous Route (Subcut), Intramuscular Route (IM). Based on End User, the market is segmented into Adult Vaccines, and Paediatric Vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Vaccines Market

The global vaccines market is experiencing significant growth driven by a surge in infections from various diseases, including influenza, HPV, hepatitis, and newly emerging viruses like COVID-19 and monkeypox. Growing awareness among the population regarding the critical role of immunization in minimizing healthcare burdens is prompting governments and health organizations to bolster their vaccination initiatives aimed at curbing disease outbreaks. Additionally, in many developing regions, initiatives by organizations such as GAVI are facilitating access to essential vaccines and enhancing market reach. As pathogens continue to evolve and new threats emerge, the need for comprehensive vaccine coverage becomes increasingly vital, fostering sustained growth in both public and private healthcare sectors.

Restraints in the Global Vaccines Market

The global vaccines market faces significant constraints due to the prolonged and intricate process of vaccine development, which demands a substantial investment in scientific resources and financial capital. This lengthy journey includes numerous clinical trials, regulatory approvals, and the complexities of cold-chain logistics, all of which contribute to a high financial burden for manufacturers. As many candidates encounter setbacks during the clinical phases, those investments become sunk costs. Furthermore, the production of biologics requires advanced infrastructure and skilled labor, making it difficult for smaller companies to compete effectively. Consequently, the high costs associated with entry and development may hinder innovation and market growth, particularly in response to emerging pathogens.

Market Trends of the Global Vaccines Market

The global vaccines market is undergoing a significant transformation driven by advancements in vaccine technologies, particularly following the success of mRNA platforms during the COVID-19 pandemic. This has prompted substantial investments from pharmaceutical and biotech companies into mRNA and other innovative vaccine modalities such as viral vector, DNA-based, and nanoparticle vaccines. These technologies not only enhance efficacy and safety but also improve the speed of response to emerging infectious diseases and enable the development of personalized vaccines. As biotechnology progresses, the landscape of the vaccine market is evolving toward next-generation platforms, fostering increased R&D investments and strategic partnerships to secure competitive advantages within this dynamic sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Vaccines Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Conjugate Vaccines
• Recombinant Vaccines
• Inactivated & Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Viral Vector Vaccines
• MRNA Vaccines
• Other Vaccines

Global Vaccines Market Size by Type & CAGR (2026-2033)

• Market Overview
• Multivalent Vaccines
• Monovalent Vaccines

Global Vaccines Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Pneumococcal Disease
• Influenza
• Combination Vaccines
• HPV
• Meningococcal Disease
• Herpes Zoster
• Rotavirus
• MMR
• Varicella
• Hepatitis
• DTP
• Polio
• RSV
• Other Disease Indications

Global Vaccines Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral Route (PO)
• Intranasal Route (NAS)
• Subcutaneous Route (Subcut)
• Intramuscular Route (IM)

Global Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Adult Vaccines
• Pediatric Vaccines

Global Vaccines Market Size & CAGR (2026-2033)

• North America (Technology, Type, Disease Indication, Route of Administration, End User)
  • US
  • Canada
• Europe (Technology, Type, Disease Indication, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Type, Disease Indication, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Type, Disease Indication, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Type, Disease Indication, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK-Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt., Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incepta Pharmaceuticals Ltd. (Bangladesh)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Farma (Indonesia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations